SynthesisFrontiers in medicine2023
The outcome and the risk factors of mucormycosis among patients with hematological diseases: a systematic and meta-analysis.
Synthesis in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 12 citations in OpenAlex.
- Algorithm-based approach to the management of rhino-maxillary mucormycosis: part II of a two-part study.BMC oral health · 2026Article
- Rhino-orbito-cerebral mucormycosis (ROCM) in eastern Iran: a six-year dual-center retrospective observational study of 329 patients.BMC infectious diseases · 2026Observational
- A Fatal Case of Disseminated Mucormycosis in a Patient Shortly after Starting Treatment against Malignant Lymphoma.Internal medicine (Tokyo, Japan) · 2026Article
- Fatal Pulmonary Mucormycosis in a Renal Transplant Recipient: A Missed Opportunistic Infection.Cureus · 2026Article
- Breakthrough rhino-orbito-cerebral mucormycosis caused byFrontiers in medicine · 2026Review
- Novel diagnostic approaches and therapeutic management of mucormycosis: insights from a retrospective monocentric cohort study.Frontiers in medicine · 2026Article
- Fatal Cutaneous Mucormycosis Initially Misdiagnosed as Necrotizing Fasciitis in an Uncontrolled Diabetic Patient: A Case Report Highlighting Diagnostic Delay.International medical case reports journal · 2026Article
- Article
- The Contribution of Human Antimicrobial Peptides to Fungi.International journal of molecular sciences · 2025Review
- Case Report: Immune checkpoint inhibitor exhibits dual benefits for a refractory lymphoma patient with disseminated mucormycosis.Frontiers in medicine · 2025Article
- Impact of Underlying Malignancy Status on Clinical Characteristics and Mortality in Pulmonary Mucormycosis: A Retrospective Cohort Study.Infection and drug resistance · 2025Article
- Rhino-orbital-cerebral mucormycosis in acute myeloid leukemia patients: a case series from Sri Lanka.BMC infectious diseases · 2024Article
- Epidemiology, Clinical, Radiological and Biological Characteristics, and Outcomes of Mucormycosis: A Retrospective Study at a French University Hospital.Journal of fungi (Basel, Switzerland) · 2024Article
- The Rising Threat of Mucormycosis: Oman's Experience Before and During the COVID-19 Pandemic.Journal of fungi (Basel, Switzerland) · 2024Article
- Corona-Associated Mucormycosis: Case Series Reports and Review of the Literature.Journal of fungi (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Methods: We scoured PubMed, Embase, and Web of Science for original papers exploring the intersection of Mucormycosis and Hematological Diseases (from 2000 to 2022). We scrutinized the overall mortality across three distinct periods, as well as differentiating between high-income and middle-income nations. We further evaluated the pooled mortality and the risk differential (RD) across several subgroups. Results: The overall mortality rate for hematology patients with mucormycosis was 61%, within a 95% confidence interval (CI) of 0.54-0.68. A significant observation was that mortality rates were somewhat lower in high-income countries compared to middle-income countries (0.60 versus 0.64, Conclusion: Despite the high mortality rates associated with mucormycosis in patients with hematological disorders, those receiving both medical and surgical interventions, as well as those with isolated infection sites, exhibited improved survival outcomes. Conversely, factors such as gender, the presence of breakthrough infection, the use of mucor-active drugs before mucor infection, and multi-drug administration did not significantly influence patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.